script.reportAU
Haematology

Lenalidomide

Brand: Lenalide®

PBAC's latest decision on Lenalidomide: Recommended with restriction (2023). Considered for Treatment of newly diagnosed multiple myeloma (as monotherapy, doublet therapy, or triplet therapy), progressive multiple myeloma, relapsed/refractory multiple myeloma (including triple combination therapy with elotuzumab or carfilzomib), and myelodysplastic syndrome.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
15
first 2008
PBS spend
$85M
47,638 scripts · 2024

Eligible population

Patients with newly diagnosed multiple myeloma (NDMM), progressive multiple myeloma, relapsed/refractory multiple myeloma (RRMM), and myelodysplastic syndrome requiring lenalidomide therapy in various treatment combinations (monotherapy, doublet, or triplet therapy).

Therapy area
Haematology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Revlimid (lenalidomide) 5 mg, 10 mg, 15 mg, and 25 mg strengths
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated.
ICER (historical)
$15k/QALY–$45k/QALY across 7 submissions (2008–2019) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

PBS expenditure

The Australian government paid $85M in PBS benefits for Lenalidomide in 2024 across 47,638 scripts, at $1,773 per script.

Submission history

Similar precedents

Open on full dashboard →